Amarin Offers New Clinical, Pre-Clinical Data at ACC Meeting Related to Effect of EPA Therapy in Statin-Treated Patients

Amarin Corporation plc AMRN today announced two posters presented yesterday at the annual meeting of the American College of Cardiology (ACC). This research adds to the growing body of clinical and pre-clinical data relevant to the use of EPA with statins. The first poster, "Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Statin-Treated Patients With Elevated Cardiovascular Risk and Very High Triglyceride Levels: Results From the MARINE Study," is an exploratory subgroup analysis of results from Amarin's MARINE trial of Vascepa® (icosapent ethyl) and observed that, compared to placebo in statin-treated patients with elevated cardiovascular risk and very high triglycerides (TGs), Vascepa administered at 4 g/day significantly lowered TGs and improved other parameters relevant to cardiovascular health without raising LDL ("bad") cholesterol. The MARINE study and this subgroup analysis were led by Harold Bays, MD, Medical Director and President, Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY. The second poster, a pre-clinical study titled, "Eicosapentaenoic Acid and Atorvastatin Active Metabolite, Alone or in Combination, Reversed Glucose- and Oxidized LDL-Induced Endothelial Dysfunction Measured Ex Vivo in Rats," noted that, independently and in combination, EPA and the active metabolite of atorvastatin improved endothelial function measured in rat kidney sections. This pre-clinical research was led by R. Preston Mason, Ph.D., Department of Medicine, Division of Cardiology, Brigham & Women's Hospital, Harvard Medical School, and president and founder, Elucida Research LLC. "The results of these two studies add to the growing body of clinical and pre-clinical data on the effects of EPA when combined with statins under the conditions studied," said Steven Ketchum, Ph.D., president of research and development and chief scientific officer at Amarin. "Amarin's REDUCE-IT trial, examining the effect of EPA therapy on top of statin therapy in at-risk patients with elevated triglycerides has reached target enrollment and will provide needed cardiovascular outcomes data for this important patient population."